Precision BioSciences 株価情報 (NASDAQ: DTIL)

最新ニュース Precision BioSciences (NASDAQ:DTIL) 株価情報

Precision BioSciences

Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.

Precision BioSciences, Inc. - Common Stock

Precision BioSciences Inc

News

Offerings

BNED

Barnes & Noble Education Files For Mixed Shelf Of Up To $100M

Management

ATKR

Atkore Inc Announced John W. Pregenzer As Chief Operating Officer In Addition To His Current Role As President-Electrical

Fourth Quarter-to-Date Comparable Sales Increased 10% Year-Over-Year
Company Reaffirms Fiscal 2025 Guidance
Participating in 2025 ICR Conference, January 13, 2025
Genesco Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCO#NYSE">GCO</a>) announced today that comparable sales, including both stores and direct sales, increased 10% for the quarter-to-date period ended December 28, 2024. Same store sales increased 6% and sales for the Company's e-commerce businesses increased 20% on a comparable basis for that period. Comparable sales changes for each retail business for the period were as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="2" rowspan="1">
Quarter-to-Date (8 weeks ended December 28, 2024)
Comparable Sales vs. FY24
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Journeys Group</td>
<td colspan="1" rowspan="1">14%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Schuh Group</td>
<td colspan="1" rowspan="1">3%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Johnston &amp; Murphy Group</td>
<td colspan="1" rowspan="1">-1%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Comparable Sales</td>
<td colspan="1" rowspan="1">10%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Same Store Sales</td>
<td colspan="1" rowspan="1">6%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Comparable E-commerce Sales</td>
<td colspan="1" rowspan="1">20%</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

Earnings

Genesco Reports Q4-To-Date Comparable Sales Increased 10% YoY; Same Store Sales Increased 6% And Sales For The Co's E-Commerce Businesses Increased 20% On A Comparable Basis For That Period

NEOG

Neogen Files For Non-Timely 10-Q With U.S. SEC; Expects To Record An Impairment Charge Of $461.4M In Q2; Expects Form 10-Q Will Report Net Loss Of $456.3M For Qtr Ended Nov 30, 2024

2024 Fourth Quarter and Full-Year Financial Results
<ul>
<li>Preliminary revenue was approximately $11.7 million for the year, compared to $12.1 million in the prior year. While year-over-year revenues for consumable products increased by approximately 3%, overall revenue was down year-over-year due to lower revenues from capital sales of Pheno instruments compared to the prior year. &nbsp;</li>
<li>Ended the year with approximately $16.3 million in cash and cash equivalents, compared to $20.9&nbsp;million at the start of the fourth quarter, a reduction in cash and cash equivalents for the fourth quarter of 2024 of $4.5 million. This reflects our continued reduction in operating cash use over the prior quarters of 2024.</li>
</ul>

Guidance

AXDX

Accelerate Q4 Revenue Of $11.7 Vs $12.1M YoY, $16.3M Cash Ending 2024; 3% Rise In Consumable Revenue Amid Pheno Capital Sales Decline

Based on holiday results, the Company has updated its fiscal 2024 outlook. The Company now expects revenue growth, including retail sales and credit card revenues, of 1.5 to 2.5 percent versus the 53-week fiscal 2023, which includes an approximately 135 basis point unfavorable impact from the 53rd week, compared with its prior outlook of flat to 1.0 percent growth. Additionally, the Company expects comparable sales growth of 2.5 to 3.5 percent versus 52 weeks in fiscal 2023, compared with its prior outlook of 1.0 to 2.0 percent growth.

Nordstrom Updates Outlook, Now Sees Revenue Growth, Including Retail Sales And Credit Card Revenues, Of 1.5%-2.5% YoY Vs Prior Outlook Of 1% Growth; Expects Comparable Net Sales Growth Of 2.5%-3.5% YoY Vs Prior Outlook Of 1%-2% Growth

Nordstrom, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) today announced a total Company net sales increase of 4.9 percent and a comparable sales increase of 5.8 percent for the nine-week holiday period ended January 4, 2025, compared with the nine weeks ended December 30, 2023. For the Nordstrom banner, net sales increased 3.7 percent and comparable sales increased 6.5 percent, while Nordstrom Rack banner net sales increased 7.4 percent and comparable sales increased 4.3 percent.

Nordstrom Announces A Total Company Net Sales Increase Of 4.9% And A Comparable Sales Increase Of 5.8% For The Nine-Week Holiday Period Ended January 4, 2025, Compared With The Nine Weeks Ended December 30, 2023. For The Nordstrom Banner, Net Sales Increased 3.7% And Comparable Sales Increased 6.5%, While Nordstrom Rack Banner Net Sales Increased 7.4% And Comparable Sales Increased 4.3%

The earnings results for WD-40 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDFC#NASDAQ">WDFC</a>) for Q1 were made public on Friday, January 10, 2025 at 04:05 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
WD-40 beat estimated earnings by 8.0%, reporting an EPS of $1.39 versus an estimate of $1.29.
Revenue was up $13.08 million from the same period last year.
<h3>Previous Earnings Records</h3>
Last quarter the company missed on EPS by $0.11 which was followed by a 5.0% drop in the share price the next day.
Here's a look at WD-40's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.34</td>
<td>1.38</td>
<td>1.11</td>
<td>1.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.23</td>
<td>1.46</td>
<td>1.14</td>
<td>1.28</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>149.19M</td>
<td>145.80M</td>
<td>140.51M</td>
<td>134.37M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>155.99M</td>
<td>155.04M</td>
<td>139.10M</td>
<td>140.42M</td>
</tr>
</tbody>
</table>

To track all earnings releases for WD-40 <a href="https://www.benzinga.com/quote/WDFC/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WDFC

WD-40 Earnings Review: Q1 Summary

Reiterated Fiscal Year 2025 Guidance
The Company reiterated the following fiscal year guidance on a pro forma basis, excluding the full fiscal year financial impact of the homecare and cleaning business portfolios the Company expects to divest in fiscal year 2025 and the impacts of a favorable non-cash income tax adjustment which the Company will discuss during its first fiscal quarter earnings call:
<ul>
<li>Net sales growth is from the pro-forma 2024 results is projected to be between 6 and 11 percent with net sales between $600 million and $630 million after adjusting for estimated translation impacts of foreign currency.</li>
<li>Gross margin for the full year is expected to be between 54 and 55 percent.</li>
<li>Advertising and promotion investments are projected to be around 6 percent of net sales.</li>
<li>Operating income is projected to be between $95 million and $100 million. This range reflects anticipated growth of between 6 to 12 percent compared to 2024 pro forma results.</li>
<li>The provision for income tax is expected to be around 24 percent.</li>
<li>Diluted earnings per share is expected to be between $5.20 and $5.45 based on an estimated 13.5 million weighted average shares outstanding. This range reflects anticipated growth of between 9 to 14 percent compared to 2024 pro forma results.</li>
</ul>
"Our first quarter results reflect strong execution and significant progress on our gross margin expansion initiatives," said Sara Hyzer, WD-40 Company's vice president, finance and chief financial officer. "We achieved gross margin of 54.8 percent, up 100 basis points from the prior year quarter, moving us significantly closer to our target of 55 percent. This improvement reflects favorable sales mix, and the benefit of various supply chain initiatives executed across the globe. As we look ahead, we remain confident in achieving our fiscal year 2025 guidance," concluded Hyzer.
This guidance is expressed in good faith and is based on management's current view of anticipated results on a pro forma basis. Unanticipated inflationary headwinds and other unforeseen events may further affect the Company's financial results. Net sales guidance is adjusted for estimated translation impact of foreign currency use weighted average fiscal year 2024 foreign currency exchange rates. In the event the Company is unsuccessful in the divestiture of its assets currently held for sale, its guidance would be positively impacted by approximately $23 million in net sales, approximately $6 million in operating income, and approximately $0.33 in diluted EPS for the full fiscal year.

WD-40 Company Reiterates FY25 Guidance, Sees Net Sales Of $600M-$630M, 6%-11% Growth Vs $622.95M; Gross Margin 54-55%, Advertising/Promotion 6% Of Sales; Operating Income $95M-$100M; Income Tax Provision 24%, EPS $5.20-$5.45 Vs $5.36 Est.

At least 10 people have been killed in the Los Angeles fires this week, with over 9,000 structures destroyed, according to the latest estimates <a href="https://www.latimes.com/california/live/pacific-palisades-fire-updates-los-angeles">cited</a> by the L.A. Times.
What Happened: Several wildfires broke out on Tuesday and Wednesday in Los Angeles following <a href="https://www.benzinga.com/25/01/42855962/los-angeles-ventura-counties-brace-for-windstorm-as-bad-as-it-gets-for-fire-weather">a strong windstorm</a>. While officials are slowly containing the blaze, the economic damage amounts to <a href="https://www.benzinga.com/news/25/01/42922091/spacex-apple-airbnb-and-more-companies-pitch-in-to-support-california-residents-after-wildfires-we-want-to-help">the most devastating</a> in the city&#8217;s history.
The windstorm created a severe fire risk and several fires are still burning on Friday, the Los Angeles Times <a href="https://www.latimes.com/wildfires-map/?fire=palisades">reported</a>.
The blaze that began in Pacific Palisades burned over 20,000 acres of land. As of Friday, it is 8% contained.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Every kid in the US learns of the Great Chicago Fire (2,112 acres) in school and how modern building codes &amp; fire depts have made this impossible, yet both the 2023 Lahaina &amp; the current Palisades Fire crossed 17,000 acres &#8211; 8x the size! I marked up a map of Chicago to compare. <a href="https://t.co/jXiRWUosCE">pic.twitter.com/jXiRWUosCE</a>
&mdash; Shaun Cooley (@shauncooley) <a href="https://twitter.com/shauncooley/status/1877410391443255485?ref_src=twsrc%5Etfw">January 9, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<figcaption class="wp-element-caption">The fire is nearly 10 times larger than the Great Chicago Fire of 1871. Analysts project the total economic damage to range from $50 billion to $150 billion, <a href="https://www.washingtonpost.com/business/2025/01/09/los-angeles-wildfire-economic-losses/">according </a>to the Washington Post.</figcaption></figure>
The Eaton Fire in Altadena and the San Gabriel Valley has burned over 13,000 acres and is merely 3% contained. Other fires are burning north of Calabasas and near Santa Clarita.
Over 200,000 Californians were without power on Friday, <a href="https://poweroutage.us/">according </a>to Power Outage.
Experts <a href="https://www.bbc.com/news/articles/c0ewe4p9128o">attribute </a>the increase in wildfires in recent years to the effects of climate change.
Why it Matters: Several companies with operations in Los Angeles are exposed to the fires.
Shares of Edison International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>), the region&#8217;s utility provider, have tumbled more than 18% since Monday. Sempra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>), another utility provider, saw its shares sink more than 10%.
Insurance providers Chubb Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>), Travelers Companies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) and Allstate Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>) saw their share prices deep in the red on Friday. Shares of Mercury General Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCY#NYSE">MCY</a>) fell over 20%.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42922299/wall-street-tumbles-on-blowout-payrolls-oil-rallies-to-76-us-dollar-hits-26-month-highs-whats-driving-markets-friday">Wall Street Tumbles On Blowout Payrolls, Oil Rallies To $76, US Dollar Hits 26-Month Highs: What&#8217;s Driving Markets Friday? </a></li>
</ul>
Image: Shutterstock

Equities

Markets

10 Dead, 9,000 Structures Damaged In Los Angeles Wildfires: The Latest

WD-40 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDFC#NASDAQ">WDFC</a>) reported quarterly earnings of $1.39 per share which beat the analyst consensus estimate of $1.29 by 7.75 percent. This is a 8.59 percent increase over earnings of $1.28 per share from the same period last year. The company reported quarterly sales of $153.50 million which beat the analyst consensus estimate of $147.47 million by 4.08 percent. This is a 9.31 percent increase over sales of $140.42 million the same period last year.

Earnings Beats

WD-40 Q1 EPS $1.39 Beats $1.29 Estimate, Sales $153.50M Beat $147.47M Estimate

<h3>Gainers</h3>
<ul>
<li>Vision Marine Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMAR#NASDAQ">VMAR</a>) stock increased by 50.0% to $2.28 during Friday's pre-market session. The market value of their outstanding shares is at $6.4 million. </li>
<li>Arhaus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) stock increased by 13.84% to $10.77. The company's market cap stands at $1.5 billion. </li>
<li>China Automotive Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAAS#NASDAQ">CAAS</a>) stock moved upwards by 12.12% to $4.44. The market value of their outstanding shares is at $134.0 million. </li>
<li>Wah Fu Education Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAFU#NASDAQ">WAFU</a>) stock moved upwards by 9.7% to $1.83. The market value of their outstanding shares is at $8.1 million. </li>
<li>Jowell Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JWEL#NASDAQ">JWEL</a>) stock rose 8.27% to $3.28. The company's market cap stands at $7.1 million. </li>
<li>Amesite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMST#NASDAQ">AMST</a>) stock rose 8.14% to $2.92. The market value of their outstanding shares is at $8.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Emerson Radio (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MSN#AMEX">MSN</a>) stock declined by 9.2% to $0.49 during Friday's pre-market session. The company's market cap stands at $10.3 million. </li>
<li>Faraday Future (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) stock decreased by 8.18% to $1.91. The market value of their outstanding shares is at $86.5 million. </li>
<li>ATA Creativity Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AACG#NASDAQ">AACG</a>) stock fell 8.08% to $0.9. The company's market cap stands at $28.3 million. </li>
<li>China Liberal Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLEU#NASDAQ">CLEU</a>) shares declined by 7.43% to $3.24. The market value of their outstanding shares is at $94.7 million. </li>
<li>MGO Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGOL#NASDAQ">MGOL</a>) stock decreased by 7.05% to $0.52. The company's market cap stands at $2.3 million. </li>
<li>Mobileye Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) stock fell 6.91% to $15.78. The market value of their outstanding shares is at $12.7 billion. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AACG

AMST

ARHS

CAAS

CLEU

FFIE

JWEL

MBLY

MGOL

VMAR

WAFU

12 Consumer Discretionary Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) shares moved upwards by 49.8% to $6.74 during Friday's pre-market session. The company's market cap stands at $51.7 million. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) stock increased by 36.44% to $1.61. The market value of their outstanding shares is at $4.0 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares rose 32.8% to $0.11. The market value of their outstanding shares is at $13.0 million. </li>
<li>Akoya Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>) stock rose 24.06% to $3.3. The market value of their outstanding shares is at $163.5 million. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) shares rose 22.83% to $4.25. The market value of their outstanding shares is at $3.6 million. </li>
<li>Senseonics Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SENS#AMEX">SENS</a>) stock increased by 18.33% to $0.51. The company's market cap stands at $303.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>IGM Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGMS#NASDAQ">IGMS</a>) stock fell 67.8% to $2.0 during Friday's pre-market session. The market value of their outstanding shares is at $118.9 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) stock declined by 31.8% to $0.92. The company's market cap stands at $17.3 million. </li>
<li>Mersana Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRSN#NASDAQ">MRSN</a>) shares decreased by 18.47% to $1.06. The company's market cap stands at $130.9 million. </li>
<li>Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) stock declined by 13.8% to $19.87. The market value of their outstanding shares is at $2.0 billion. </li>
<li>TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) stock declined by 13.18% to $62.99. The market value of their outstanding shares is at $2.1 billion. </li>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) stock declined by 12.36% to $1.49. The company's market cap stands at $60.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKYA

CLDI

DHAI

DTIL

IGMS

MRSN

SCNI

SENS

TMDX

ZVSA

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Microvast Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) shares moved upwards by 38.5% to $2.59 during Friday's pre-market session. The market value of their outstanding shares is at $834.3 million. </li>
<li>Bridger Aerospace Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAER#NASDAQ">BAER</a>) shares increased by 31.89% to $3.68. The company's market cap stands at $199.4 million. </li>
<li>Zoomcar Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) stock increased by 19.66% to $2.13. The company's market cap stands at $11.2 million. </li>
<li>Hyperscale Data (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#AMEX">GPUS</a>) stock increased by 15.99% to $4.93. The market value of their outstanding shares is at $5.4 million. </li>
<li>Art's-Way Manufacturing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTW#NASDAQ">ARTW</a>) shares moved upwards by 12.47% to $2.07. The company's market cap stands at $10.4 million. </li>
<li>Ming Shing Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSW#NASDAQ">MSW</a>) stock rose 12.18% to $5.8. The company's market cap stands at $75.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ZIM Integrated Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) stock fell 9.6% to $18.74 during Friday's pre-market session. The company's market cap stands at $2.2 billion. </li>
<li>SolarMax Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMXT#NASDAQ">SMXT</a>) stock fell 8.58% to $1.28. The company's market cap stands at $57.9 million. </li>
<li>Shengfeng Development (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFWL#NASDAQ">SFWL</a>) shares declined by 8.5% to $0.97. The company's market cap stands at $80.0 million. </li>
<li>KULR Tech Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KULR#AMEX">KULR</a>) stock declined by 7.92% to $2.56. The company's market cap stands at $612.5 million. </li>
<li>American Rebel Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) stock decreased by 7.49% to $2.1. The market value of their outstanding shares is at $3.4 million. </li>
<li>Ameresco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRC#NYSE">AMRC</a>) shares declined by 7.24% to $25.14. The market value of their outstanding shares is at $1.3 billion. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMRC

AREB

ARTW

BAER

GPUS

KULR

MVST

SFWL

SMXT

ZCAR

12 Industrials Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>MicroCloud Hologram (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NASDAQ">HOLO</a>) stock rose 26.9% to $2.69 during Friday's pre-market session. The market value of their outstanding shares is at $55.2 million. </li>
<li>BIO-key Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>) shares rose 25.69% to $1.81. The market value of their outstanding shares is at $5.6 million. </li>
<li>Gryphon Digital Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) stock moved upwards by 22.82% to $0.46. The market value of their outstanding shares is at $24.0 million. </li>
<li>Boxlight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOXL#NASDAQ">BOXL</a>) shares increased by 17.62% to $1.0. The market value of their outstanding shares is at $9.8 million. </li>
<li>Rekor Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REKR#NASDAQ">REKR</a>) shares rose 15.29% to $1.88. The market value of their outstanding shares is at $176.3 million. </li>
<li>WISeKey Intl Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKEY#NASDAQ">WKEY</a>) stock rose 13.96% to $7.49. The market value of their outstanding shares is at $83.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>LeddarTech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDTC#NASDAQ">LDTC</a>) stock declined by 17.5% to $1.13 during Friday's pre-market session. The company's market cap stands at $40.3 million. </li>
<li>Lightwave Logic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWLG#NASDAQ">LWLG</a>) stock decreased by 15.84% to $1.86. The market value of their outstanding shares is at $227.6 million. </li>
<li>Nortech Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSYS#NASDAQ">NSYS</a>) stock declined by 8.74% to $9.3. The company's market cap stands at $25.6 million. </li>
<li>Cyngn (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) stock decreased by 8.54% to $0.55. The company's market cap stands at $11.8 million. </li>
<li>Gorilla Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) stock fell 8.01% to $15.39. The company's market cap stands at $171.0 million. </li>
<li>Focus Universal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCUV#NASDAQ">FCUV</a>) stock fell 7.21% to $0.62. The market value of their outstanding shares is at $45.7 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BKYI

BOXL

FCUV

GRRR

GRYP

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

LDTC

LWLG

NSYS

REKR

WKEY

12 Information Technology Stocks Moving In Friday's Pre-Market Session

WIIM

SWTX

SpringWorks Therapeutics shares are trading higher amid rumors of takeover interest.

Castellum Files For Mixed Shelf Offering Up To $100M

VOXX

VOXX International Files Form 12b-25 For Late Form 10-Q Due To Impairment Analysis Following Gentex Merger Agreement

During the last three months, 11 analysts shared their evaluations of Voya Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOYA#NYSE">VOYA</a>), revealing diverse outlooks from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">9</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Voya Financial, revealing an average target of $87.64, a high estimate of $95.00, and a low estimate of $81.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 3.6%. 
<img src="https://www.benzinga.com/files/images/story/2025/1736542876_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of Voya Financial by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$82.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Kenneth Lee</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Joshua Shanker</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$83.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$92.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Thomas Gallagher</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$89.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$81.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Kenneth Lee</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$95.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$91.00</td>
<td>$88.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Voya Financial. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Voya Financial compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Voya Financial's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Voya Financial's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/VOYA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Voya Financial analyst ratings.</a>
<h2>Get to Know Voya Financial Better</h2>
Voya Financial Inc is a financial services company, which, through its subsidiaries, provides various investment, insurance, and retirement solutions to individual and institutional clients in the United States. Its products and services include tax savings plans, individual retirement accounts, group life insurance plans, and employee benefits products, among others. The company tailors each of its products to the needs of its customer base. It operates its business through three principal lines: Wealth Solutions, Investment Management, and Health Solutions The Wealth segment generates roughly half of the company's revenue.
<h3>Voya Financial: Delving into Financials</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Over the 3 months period, Voya Financial showcased positive performance, achieving a revenue growth rate of 8.49% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Voya Financial's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 5.08%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Voya Financial's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.24%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Voya Financial's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.06%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.77.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

VOYA

A Glimpse Into The Expert Outlook On Voya Financial Through 11 Analysts

In the latest quarter, 5 analysts provided ratings for Oceaneering International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OII#NYSE">OII</a>), showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $27.8, with a high estimate of $34.00 and a low estimate of $22.00. This current average has increased by 4.91% from the previous average price target of $26.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1736542855_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Oceaneering International. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Marc Bianchi</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$27.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$26.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$22.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Kurt Hallead</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Oceaneering International. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Oceaneering International compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Oceaneering International's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Oceaneering International's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OII/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Oceaneering International analyst ratings.</a>
<h2>Discovering Oceaneering International: A Closer Look</h2>
Oceaneering International Inc is a global provider of engineered services and products robotic solutions to the offshore energy, defense, aerospace, manufacturing and entertainment industries. Most of Oceaneering's products are produced for the offshore oil and gas market. It had a 2020 segment realignment to promote synergies and cost efficiency. The five segments are subsea robotics; manufactured products; offshore projects group; integrity management and digital solutions; and aerospace and defense technologies. Within the segments are two businesses - services and products provided primarily to the oil and gas industry. The firm is also involved in the offshore renewables and mobility solutions industries.
<h3>Understanding the Numbers: Oceaneering International's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Oceaneering International showcased positive performance, achieving a revenue growth rate of 7.03% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Energy sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Oceaneering International's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 6.07%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Oceaneering International's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 6.11%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Oceaneering International's ROA stands out, surpassing industry averages. With an impressive ROA of 1.77%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.26.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Oceaneering International Stock: Analyst Perspectives (5 Ratings)

Reports Q3 revenue $576,000, consensus $6.36M. The decrease of $12.5M in revenue during the quarter ended September 30 was primarily the result of ...

Precision BioSciences reports Q3 EPS ($2.25), consensus ($1.92)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of ...

Positive Outlook for Precision BioSciences: Buy Rating Affirmed Amid Promising Gene Editing Developments

JonesTrading analyst Soumit Roy maintained a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of $30.00. S...

Precision BioSciences: Undervalued Gene Editing Innovator with Promising Financial and Clinical Prospects

Precision BioSciences (DTIL) will present preclinical data supporting the advancement of PBGENE-HBV into clinical development. The company will als...

Precision BioSciences to present preclinical PBGENE-HBV data

Precision BioSciences (DTIL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit Roy fro...

Buy Rating for Precision BioSciences Driven by Promising Gene Editing Advancements in cHBV Therapy

BMO Capital analyst Kostas Biliouris upgraded the rating on Precision BioSciences (DTIL – Research Report) to a Buy today, setting a price target o...

Strong Buy Recommendation for Precision BioSciences: Promising Clinical Data and Favorable Valuation

BMO Capital upgraded Precision BioSciences (DTIL) to Outperform from Market Perform with an unchanged price target of $34 alter iECURE announced cl...

Precision BioSciences upgraded to Outperform from Market Perform at BMO Capital

Precision Bio rises after Phase 1/2 data for gene editing therapy in OTC deficiency

Advancements in Precision BioSciences' Gene Editing Platform Bolster Buy Rating

Precision Bio rises after gene editing data: BMO upgrades (update)

Press Releases

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B

Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress

Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024

Precision BioSciences to Report Third Quarter Results on November 4, 2024

Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B

Precision BioSciences to Participate in Upcoming November Investor Conferences

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Comments

Precision BioSciences

ニュース

最新ニュース Precision BioSciences (NASDAQ:DTIL) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル